EMA’s Revised Guide On Additional Risk Minimization ‘Overly Detailed’

EU Pharma Association Pushes For Greater Use Of Digital Formats

Executive Summary: The European pharma industry federation believes the advice provided in the updated draft EU guideline on additional risk minimization measures is far too detailed, resulting in a lack of focus, information overlap and confusion.

White pills on leaflet about possible side effects and overdose
Risk management of medicines involves activities to identify, characterize, prevent and minimize risks • Source: Alamy

Some sections of the European Medicines Agency’s revised pharmacovigilance guideline on additional risk minimization measures are “overly detailed” and their implementation could result in confusion, the EU pharmaceutical industry federation EFPIA has stated in its written feedback to the agency.

The updated draft guideline (GVP Module XVI) was issued for stakeholder consultation earlier this year. It included “pages and pages”...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography